Search results
Moderna’s New Flu-COVID Combi mRNA Vaccine Outperforms Separate Shots In Trials
IFLScience· 3 days agoPharmaceutical company Moderna has announced that a combination vaccine it has been developing...
Moderna (NASDAQ:MRNA) shareholders are still up 857% over 5 years despite pulling back 6.1% in the...
Simply Wall St. via Yahoo Finance· 4 hours agoLong term investing can be life changing when you buy and hold the truly great businesses. And...
Moderna says next-generation COVID vaccine efficacy non-inferior to current shot
Reuters via Yahoo News· 1 day agoThe experimental vaccine, which met the main trial goal, was being tested in more than 11,000 people...
Oppenheimer Increases Moderna (NASDAQ:MRNA) Price Target to $179.00
ETF DAILY NEWS· 14 hours agoModerna (NASDAQ:MRNA – Get Free Report) had its target price hoisted by analysts at Oppenheimer from $163.00 to $179.00 in a research report issued to clients and investors ...
Moderna’s Covid-19 vaccine meets primary efficacy endpoint in Phase III trial
Clinical Trials Arena via Yahoo Finance· 9 hours agoModerna has announced that its Phase III clinical trial of the investigational next-generation...
Combined flu and Covid vaccine from Moderna shows positive results
dpa international via Yahoo News· 4 days agoA combined flu and Covid vaccine from Moderna provokes a higher immune response than separate single...
Pentagon ran secret anti-vax campaign to undermine China during pandemic
USA TODAY via Yahoo News· 1 hour ago-made vaccines that became available later, Lucey and others said. Although the Chinese vaccines...
Moderna Falls, Though Says Covid/Flu Shot Topped Rivals
Investor's Business Daily· 4 days agoIn a study of about 8,000 people, Moderna's combination vaccine proved it's not inferior to the...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoModerna stock is making a turnaround after the Food and Drug Administration approved its second-ever...
Why Moderna Stock Is a No-Brainer Buy Right Now | The Motley Fool
The Motley Fool· 4 days agoIn 2022, the biotech company generated sales of nearly $18.9 billion, but it expects revenue of only...